Skip to main content
. 2024 Dec 15;16(12):4675–4684. doi: 10.4251/wjgo.v16.i12.4675

Table 2.

Systemic therapy, n (%)

Feature
n = 38
First-line treatment
      Temozolomide/capecitabine 35 (92.1)
      CAPOX 1 (2.6)
      Cisplatin/etoposide 1 (2.6)
      Interferon alpha 1 (2.6)
First-line cycles
      Median (IQR) 9 (6-22.75)
Duration of first-line treatment, days
      Median (IQR) 331 (133.25-606)
Second-line treatment
      Yes 14 (36.8)
      No 24 (63.2)
Second-line regimen, n = 14
      Capecitabine 4 (28.6)
      CAPOX 3 (21.4)
      TEMCAP 3 (21.4)
      Cisplatin/etoposide 1 (7.1)
      Dacarbazine (DTIC) 1 (7.1)
            GEMOX 1 (7.1)
      Temozolomide 1 (7.1)

IQR: Interquartile range; TEMCAP: Temozolomide and capecitabine regimen; CAPOX: capecitabine/oxaliplatin; GEMOX: gemcitabine/oxaliplatin.